Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

September 17, 2008 16:00 ET

Ambrilia to Present at BioContact 2008

MONTREAL, QUEBEC--(Marketwire - Sept. 17, 2008) - Ambrilia Biopharma Inc. (TSX:AMB) today announced that Dr. Philippe Calais, President and CEO, will present the Company and its projects at BioContact Quebec 2008 to be held in Quebec City, October 1-3. This presentation will take place on Wednesday, October 1, Laval room (Chateau Frontenac), at 2:00 pm local time.


Ambrilia Biopharma Inc. (TSX:AMB) is a biotechnology company focused on the discovery and development of novel treatments for viral diseases and cancer. The Company's strategy aims to capitalize on its broad portfolio and original expertise in virology. Ambrilia's product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a therapeutic peptide for prostate cancer, a targeted delivery technology for cancer, an HIV protease inhibitor program (exclusive worldwide rights granted to Merck & Co., Inc.) as well as HIV integrase and entry inhibitors, Hepatitis C inhibitors and anti-Influenza A compounds. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France.

For more information, please visit the Company's web site:

Contact Information